Image source: National Cancer Institute on Unsplash
Germany is one of the leading nations in pharmaceutical research - but global competition is increasing. While technological advances such as artificial intelligence and big data are accelerating the development of new active ingredients, German pharmaceutical companies are facing the challenge of maintaining their innovative strength. In addition to high investments in research and development, qualified specialists are crucial for success. But this is precisely where a bottleneck is looming. How can the industry leverage its locational advantages and remain competitive in the long term?
The development of new drugs is a lengthy and cost-intensive process. It takes an average of 12 to 15 years from the initial idea to market approval. Only one in 5,000 to 10,000 tested substances makes it to approval. According to the German Chemical Industry Association (VCI), around 15.5 billion euros will be invested in research and development (R&D) in the chemical and pharmaceutical industry in Germany alone in 2023.
The integration of big data and artificial intelligence (AI) is crucial for the competitiveness of the German pharmaceutical industry. More and more companies are turning to digital solutions to accelerate the development of new active ingredients and reduce costs. AI-supported analysis methods make it possible to identify potential active ingredients in a more targeted manner and to design preclinical and clinical studies more efficiently.
A decisive competitive advantage is and remains the dense network of highly qualified research institutions, including renowned universities and non-university institutes such as Max Planck, Leibniz and Fraunhofer Institutes as well as Helmholtz Centers. Innovative biotech start-ups continue to emerge from these institutions, enriching the industry with new technologies and therapies.
According to the German Association of Research-Based Pharmaceutical Companies (vfa), German pharmaceutical companies benefit in particular from highly qualified, motivated and responsible employees. In 2023, around 18,000 specialists worked in research and development (R&D) - a fifth of all employees in the industry.
Despite the positive development, the industry is facing challenges. The shortage of skilled workers is becoming increasingly noticeable, particularly in the areas of biotechnology, clinical research and regulatory affairs. Companies must therefore focus more on targeted talent management and recruiting.
A competent team of experts is the prerequisite for success in the international competition of pharmaceutical research. With the BESTMINDS consultants at your side, you will find the qualified specialists for your research and development projects.
Please contact us for an individual consultation.
